AI Earnings Predictions for Dermata Therapeutics Inc. (DRMA)

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 –

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN DIEGO, CA, August 11, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.

“Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we’ve identified the untapped ‘white space’ to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues in the near future while continuing to build long-term value for our shareholders,” continued Mr. Proehl. “Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to come,” concluded Mr. Proehl.

Corporate Highlights

●Attended first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand. In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and provided attendees with more information on the upcoming launch of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa, and wellness professionals with over 400+ brands in attendance.

●Began social media campaign for its new skincare brand, Tome. The Company recently unveiled the Tome brand’s official social media presence as part of the Company’s broader commercial launch strategy. These efforts are designed to increase brand awareness, engage prospective consumers, and support the successful ecommerce launch of the Company’s first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.

Anticipated Upcoming Milestones

●Launch first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application.

●Continue development of a second DTC product. The Company is also working on its second skincare product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected to launch sometime after its Foundational Treatment.

Second Quarter 2026 Financial Results

As of June 30, 2026, the Company had $4.4 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $3.1 million decrease in cash and cash equivalents for the six months ended June 30, 2026, resulted from $4.9 million of cash used in operations, and $0.1 million of cash used in investing activities, offset by approximately $1.9 million of ATM financing proceeds. The Company expects its current cash resources to be sufficient to fund operations into the fourth quarter of 2026.

Research and development expenses were $0.2 million for the quarter ended June 30, 2026, compared to $0.6 million for the quarter ended June 30, 2025. The $0.4 million decrease in research and development expenses resulted primarily from the Company’s decision to prioritize the commercial launch of its first product, resulting in a decrease in research and development efforts during the three months ended June 30, 2026. As the Company continues to focus on branding, marketing, and manufacturing of its first commercial product, the Company reallocated its resources, including employee efforts, toward the pre-commercial launch and anticipates that research and development expenses will continue to decrease compared to prior periods.

Selling, general and administrative expenses were $2.8 mill

false 0001853816

0001853816

2026-01-01 2026-03-31

0001853816

DRMA:CommonStockParValue0.0001PerShareMember

2026-01-01 2026-03-31

0001853816

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

2026-01-01 2026-03-31

0001853816

2026-03-31

0001853816

2025-12-31

0001853816

2025-01-01 2025-03-31

0001853816

us-gaap:StockCompensationPlanMember

2026-01-01 2026-03-31

0001853816

us-gaap:StockCompensationPlanMember

2025-01-01 2025-03-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

xbrli:pure

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

- Dermata announced their Tome Skincare brand for direct-to-consumer (“DTC”) skincare products -

- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -

- Raised $2.0 million in net proceeds from it’s at-the-market (“ATM”) financing facility -

SAN DIEGO, CA, May 13, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2026.

“Since announcing our strategic pivot in September 2025, we have made meaningful progress toward becoming a direct-to-consumer commercial skincare company,” commented Gerry Proehl, Dermata’s Chairman, President, and CEO. “This pivot represents a significant landmark in our mission to deliver safe, effective, and consumer-friendly skincare products. We continue to build on that foundation during the first quarter of 2026 by advancing development of our initial product, refining our brand strategy, and aligning our operations to support commercialization. We are currently finalizing product packaging, putting the finishing touches on the Tome skincare website and getting ready to initiate consumer use studies to provide clinical data to support our upcoming product launches,” Mr. Proehl continued. “As we look ahead, we remain focused on executing our planned mid-2026 launch of our once-weekly Foundational Treatment for skin renewal that we believe will bring an in-office-like treatment into the hands of consumers. We believe this product launch will position Dermata to deliver long-term value for both consumers and shareholders,” concluded Mr. Proehl.

Corporate Highlights

●Announced its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce professional skincare at home. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to the Tome skincare portfolio that utilize time-tested remedies to simplify skincare routines, first starting with a once-weekly Foundational Treatment for skin renewal.

●Announced the hiring of Kyra Peckaitis as Vice President of Marketing. In March 2026, Ms. Peckaitis joined the Dermata team to lead its new Tome skincare brand. Prior to joining Dermata, Ms. Peckaitis worked at Coterie helping to build its DTC baby care brand. Ms. Peckaitis brings years of experience in DTC marketing and brand building.

●Raised $ 2.0 million in net proceeds in Q1 2026. The funds raised during Q1 2026 from the Company’s ATM are expected to help fund Dermata’s operations into the first quarter of 2027.

Anticipated Upcoming Milestones

●Launch first DTC product, Foundational Treatment, in the middle of 2026. The Company is finalizing packaging for the upcoming launch of its Foundational Treatment. The Company believes the Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application. The Company anticipates being ready to launch the Foundational Treatment in the middle of 2026.

●Continue to prepare for the launch of a second DTC product. The Company is also working on its second DTC product which is expected to launch after its Foundational Treatment.

First Quarter 2026 Financial Results

As of March 31, 2026, the Company had $6.9 million in cash and cash equivalents, compared to $7.5 million as of December 31, 2025. The $0.6 million decrease in cash and cash equivalents for the quarter ended March 31, 2026, resulted from approximately $2.0 million of ATM financing proceeds which were decreased by approximately $0.1 million from equity financing-related expenses, offset by $2.5 million of cash used in operations. The Company expects its current cash resources to be sufficient to fund operations into the first quarter of 2027.

Research and development expenses were $0.4 million for the quarter ended March 31, 2026, compared to $1.3 million for the quarter ended March 31, 2025. The $0.9 million decrease in research and development expenses was the result of $0.7 million of decreased clini

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer (“DTC”) skincare products under the brand name Tome -

- Dermata plans to launch its first DTC product, our Foundational Treatment, a once-weekly mask to support a skin renewal, in the middle of 2026 -

- Raised $4.125 million in gross proceeds from a private placement financing in December 2025, including participation from Dermata’s Chief Executive Officer, Chief Financial Officer, and a member of the Company’s management -

SAN DIEGO, CA, March 26, 2026 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) (“Dermata,” or the “Company”), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2025.

“We are extremely excited as we approach the planned launch of our first DTC product in the middle of 2026, as this will be an important milestone in our company’s evolution,” said Gerry Proehl, Chairman, President, and CEO of Dermata. “Our team has been extremely busy over the past few months since we announced in September 2025 our strategic pivot to sell direct-to-consumer skincare products. Since the announcement, we have recently revealed our new skincare brand, Tome, hired a new Vice President of Marketing to lead the brand, and are close to finalizing the commercial packaging for our first product,” Mr. Proehl continued. “We believe we can leverage our deep knowledge from years of clinical dermatology to deliver DTC skincare products that are efficacious and accessible to consumers. With the cash raised from our recent financings, we believe we are in a good financial position for our planned product launches, with potential revenue to follow,” concluded Mr. Proehl.

Kyra Peckaitis, Dermata’s new Vice President of Marketing, commented, “Having recently joined Dermata, I’ve been incredibly energized by both the strength of the team and opportunity to create something truly differentiated in the skincare market. We are very excited to announce our first product by Tome, our Foundational Treatment, a once-weekly, foundational step designed to renew the appearance of the skin and improve tone and texture over time. Our Foundational Treatment will incorporate our hero ingredient, Spongilla lacustris, a wildly harvested freshwater sponge that we call Bioneedle, to provide consumers with the feel of an aesthetician treatment at home.” Ms. Peckaitis continued, “We decided to fast-track the launch of the Foundational Treatment as we see this product reaching a larger market, which can be used as the base product for any skincare routine. We continue to diligently work on our second product, our Clearing Treatment for acne, which we expect to launch for the sizable acne market shortly after launching our Foundational Treatment. In a crowded skincare landscape, we see a real opportunity to stand out by offering solutions that simplify routines while delivering meaningful improvements in how consumer’s skin looks and feels, and we believe our Foundational Treatment and Clearing Treatment will do just that.”

Corporate Highlights

● Announced strategic pivot to DTC skincare company. In September 2025, Dermata announced that it was making a strategic shift from developing prescription dermatology products to developing and commercializing DTC skincare products. The Company is currently working on branding, packaging, and manufacturing to prepare for the expected launch of its first DTC product, a once-weekly, foundational routine to support skin renewal in the middle of 2026. The Company plans to sell multiple skincare products directly to consumers and directly to aestheticians and dermatologists for in-office treatments.

● Announced the launch of its new skincare brand, Tome. In March 2026, Dermata revealed its new skincare brand, Tome, which aims to introduce “skintech” at home. The Tome skincare line will emphasize products Dermata believes can become the essential foundation of any well-rounded skincare routine. The Company plans to add multiple products to their Tome skincare portfolio that utilize time-tested remedies to simplify skincare routines.

● Announced the hiring of Kyra Peckaitis as Vice President of Marketing. In March 2026, Ms. Peckaitis joined the Dermata team to lead the launch of its new Tome skincare brand. Prior to joining Dermata, Ms. Peckaitis worked at Coterie helping to build its DTC baby care brand. Ms. Peckaitis brings years of experience in DTC marketing and brand building.

● Raised $15.4 million in gross proceeds during 2025 and beginning of 2026. The funds raised during 2025, along with the proceeds from the Company’s at-the-market facility in January 2026, are expected to fund its operations into the first quarter of 2027.

● Announced positive topline data